Differentiating the efficacy of the tumor necrosis factor inhibitorsBoulos Haraoui
Centre Hospitalier de l Universite de Montreal, Canada
Semin Arthritis Rheum 34:7-11. 2005
..The purpose of this brief review is to summarize current efficacy data and explore possible explanations for observed clinical differences...
- Differentiating the efficacy of tumor necrosis factor inhibitors
Boulos Haraoui
Centre Hospitalier de l Universite de Montreal, Montreal, Quebec, Canada
J Rheumatol Suppl 74:3-7. 2005
..In this brief review current efficacy data are summarized and possible explanations for observed clinical differences are explored...
- Musculoskeletal manifestations and autoimmune diseases related to new biologic agents
Boulos Haraoui
Universite de Montreal, RDU CHUM, Hopital Notre Dame, Montreal, Quebec, Canada
Curr Opin Rheumatol 18:96-100. 2006
..One of the most common observations made during their use is the development of autoantibodies. The purpose of this paper is to review this phenomenon and its clinical implications...
- Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept
Boulos Haraoui
Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Sherbrooke East, Montreal, Quebec H2L 4M1, Canada
J Rheumatol 31:2356-9. 2004
..To assess the efficacy and monitor serious adverse events in patients with rheumatoid arthritis (RA) switching treatment from infliximab to etanercept...
- Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes
Jean Pierre Raynauld
Osteoarthritis Research Unit, University of Montreal Hospital Centre, Notre Dame Hospital, Department of Medicine, University of Montreal, Montreal, Quebec, Canada
Arthritis Res Ther 8:R21. 2006
..These data confirm the significant advantage of qMRI for reliably measuring knee structural changes at as early as 12 months, and for identifying risk factors associated with OA progression...
- Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation
Jean Pierre Raynauld
Osteoarthritis Research Unit, University of Montreal Hospital Research Centre, Notre Dame Hospital, Montreal, Quebec, Canada
Ann Rheum Dis 70:1382-8. 2011
..To identify predictive factors for total knee replacement (TKR) using data from MRI of knee osteoarthritis patients in a phase III multicentre disease-modifying osteoarthritis drug (DMOAD) study...
- An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis
Jean Pierre Raynauld
Osteoarthritis Research Unit, University of Montreal Hospital Research Centre, Notre Dame Hospital, Montreal, Quebec, Canada
Semin Arthritis Rheum 40:185-92. 2010
..The aim of the study was to evaluate by quantitative magnetic resonance imaging the effect of celecoxib 200 mg daily on cartilage volume loss over 12 months in knee osteoarthritis...
- Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in patients with knee osteoarthritis
Jean Pierre Raynauld
Osteoarthritis Research Unit, University of Montreal Hospital Centre, Notre Dame Hospital, Montreal, Quebec, Canada
Arthritis Res Ther 10:R129. 2008
..We aimed to compare these two different approaches looking at the global knee and subregions, using data from an osteoarthritis (OA) multicentre randomised clinical trial...
- Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action
Boulos Haraoui
University of Montreal, Rheumatology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Canada
Semin Arthritis Rheum 39:176-81. 2009
....
- Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response
Boulos Haraoui
Department of Rheumatology, Centre Hospitalier de l Universite de Montreal, and Groupe de recherche des maladies rhumatismales du Québec, Montreal, Quebec, Canada
J Rheumatol 33:31-6. 2006
....
- Predictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapy
Julie Drouin
Department of Medicine, Centre Hospitalier de l Universite de Montreal, Universite de Montreal, Montreal, Quebec, Canada
J Rheumatol 37:1405-10. 2010
..To determine through a systematic literature search the predictors of clinical response and radiographic progression in adult patients with rheumatoid arthritis (RA) treated with methotrexate (MTX) monotherapy...
- Interstitial pneumonitis associated with infliximab therapy
Edith Villeneuve
Department of Rheumatology, , Montreal, Quebec, Canada
J Rheumatol 33:1189-93. 2006
..Other similar cases are reviewed. Infliximab may potentiate pulmonary toxicity of MTX...
- Immunogenicity of biologic agents: a new concern for the practicing rheumatologist?
Boulos Haraoui
University of Montreal Hospital Centre, Notre-Dame Hospital, Department of Medicine, University of Montreal, Montreal, Quebec, Canada
Curr Rheumatol Rep 9:265-7. 2007
- Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review
Josiane Bourré-Tessier
Department of Medicine, Centre Hospitalier de l Universite de Montreal, Universite de Montreal, Montreal, Quebec, Canada
J Rheumatol 37:1416-21. 2010
....
- Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial
Boulos Haraoui
University of Montreal, Montreal, Quebec, Canada
J Rheumatol 38:2548-56. 2011
..Changes in patient-reported outcomes after primary treatment or retreatment with RTX and factors determining retreatment in clinical practice were also evaluated...
- Treatment of early rheumatoid arthritis: concepts in management
Boulos Haraoui
Institut de Rhumatologie de Montréal, Montreal, Quebec, Canada
Semin Arthritis Rheum 40:371-88. 2011
....
- The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis
Boulos Haraoui
University of Montreal, Montreal, Quebec, Canada
J Rheumatol Suppl 72:46-7. 2005
..The anti-TNF agents combined with optimal doses of MTX currently constitute the best therapeutic regimen for the management of patients with RA failing to adequately respond to traditional DMARD...
- Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire
Boulos Haraoui
Institut de Rhumatologie de Montréal, 1551 Ontario Street East, Montreal, Quebec, H2L 1S6, Canada
Ann Rheum Dis 70:1999-2002. 2011
..To measure the level of agreement and application of 10 international recommendations for treating rheumatoid arthritis (RA) to a target of remission/low disease activity...
- Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes
Jean Pierre Raynauld
Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, and Université de Montréal, Montreal, Quebec, Canada
Arthritis Rheum 50:476-87. 2004
..To evaluate the change in osteoarthritic (OA) knee cartilage volume over a two-year period with the use of magnetic resonance imaging (MRI) and to correlate the MRI changes with radiologic changes...
- Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study
Boulos Haraoui
Department of Rheumatology, CHUM Hopital Notre Dame, Montreal, Quebec, Canada
BMC Musculoskelet Disord 12:261. 2011
..abstract:..
- Adalimumab therapy in rheumatoid arthritis
Edward Keystone
Division of Advanced Therapeutics, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, 60 Murray Street, University of Toronto, Toronto, Ontario, Canada M5G 1X5
Rheum Dis Clin North Am 30:349-64, vii. 2004
..Taken together, the data support adalimumab as a new therapeutic option for patients with moderate to severe rheumatoid arthritis...
- Advantages and limitations of utility assessment methods in rheumatoid arthritis
Ariel Beresniak
LIRAES, University Paris Descartes, Paris, France
J Rheumatol 34:2193-200. 2007
..In light of these findings, real cost-effectiveness analyses based on observed clinical outcomes appear to be more robust and reliable to assist decision-making, particularly in the context of RA...
- Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study
Jean Pierre Pelletier
Osteoarthritis Research Unit, University of Montreal Hospital Center, 1560 Sherbrooke Street East, Montreal, QC, Canada H2L 4M1
Arthritis Res Ther 9:R74. 2007
..This study also further confirms the correlation between cartilage volume loss and JSN and symptomatic changes at 24 months...
- Is there a rationale for switching from one anti-tumor necrosis factor agent to another?
Boulos Haraoui
J Rheumatol 31:1021-2. 2004
